Coca-Cola considers putting cannabis in a health drink

Amy Baxter | | Health Exec | Policy & Regulations
coca-cola-462776_1920.jpg

The Coca-Cola Company admitted it is taking a hard look at the use of cannabis in drinks after reports emerged that the company was in talks to develop a health drink infused with cannabidiol, a compound from the cannabis plant.

Coca-Cola was rumored to be talking to Aurora Cannabis, a Canadian company that saw its shares leap 17 percent on the Toronto Stock Exchange following the reports, the Associated Press reported. Cannabidiol is a non-psychoactive compound derived from cannabis that is believed to have pain-relieving properties, according to the AP.

However, Coca-Cola attempted to temper the rumors Monday.

“We have no interest in marijuana or cannabis. Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world,” Coa-Cola said in a statement Monday. “The space is evolving quickly. No decisions have been made at this time.”

Coca-Cola’s interest in the space is indicative of growing mainstream acceptance of cannabis products across different industries, particularly as they relate to health.

See the full story below:

Coca-Cannabis? Coke analyzing cannabis in wellness drinks

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”